» 
Roger Knaggs
Roger Knaggs
A phoneA letter

Roger Knaggs

Associate professor in clinical pharmacy practice

Role in PharmNovo: Scientific advisor.

University: University of Nottingham.

Resumé: Roger has undergraduate degrees in Science (Pharmacy) and Biomedical sciences and a PhD from the University of Nottingham. He was an Advanced Pharmacy Practitioner at Nottingham University Hospital prior to his current academic appointment. He is a Fellow of the Faculty of Pain Medicine, Chair of the UK Clinical Pharmacy Association pain management group, a member of the British Pain Society Council and the UK Advisory Council on the Misuse of Drugs. He is the media spokesperson on pain management for the Royal Pharmaceutical Society and British Pain Society in both online and traditional media, including newspapers, magazines, radio and television. Roger is a specialist in the management of chronic pain with particular expertise in the clinical pharmacology of opioids.

Member of:

Latest news

View all
July 17, 2024

17.5m EUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

Read more
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more